| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AS605240 | GDSC1000 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |